Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Somatostatinoma 2Carcinoma, Islet Cell 2Breast Neoplasms 2Vipoma 1Uterine Cervical Dysplasia 1Squamous Intraepithelial Lesions 1Prostatic Neoplasms 1Pituitary Neoplasms 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, AIDS-Related 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Insulinoma 1Growth Hormone-Secreting Pituitary Adenoma 1Glucagonoma 1Gastrinoma 1Congenital Abnormalities 1Colonic Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

Melphalan 5Dexamethasone 4Bortezomib 3Arsenic Trioxide 3fludarabine phosphate 2Vorinostat 2Stem Cell Transplantation 2Peripheral Blood Stem Cell Transplantation 2Lenalidomide 2Drug Therapy 2Busulfan 2Ascorbic Acid 2ogalvibart 1ethanolamine oleate 1daratumumab 1crexavibart 1carfilzomib 1Zoledronic Acid 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Therapeutics 1Thalidomide 1Tacrolimus 1Surveys and Questionnaires 1Sulfamethoxazole 1Sodium Chloride 1Simvastatin 1Saline Solution, Hypertonic 1Saline Solution 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Neoplasms, Plasma Cell × Biological Therapy × Clear all
NCT00112879 2013-07-10

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡